Byoung Hyuck Kim1, Moon-June Cho2, Jeanny Kwon3. 1. Department of Radiation Oncology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Boramae-ro 5 gil, 20, Dongjak-gu, Seoul, Korea. 2. Department of Radiation Oncology, Chungnam National University College of Medicine, Munhwa-ro 282, Jungku, Daejeon, 35015, Korea. 3. Department of Radiation Oncology, Chungnam National University College of Medicine, Munhwa-ro 282, Jungku, Daejeon, 35015, Korea. ijeannyi@daum.net.
Abstract
PURPOSE: Numerous studies have suggested that metformin treatment can increase breast cancer survival; however, it is unclear whether its effects interact with intrinsic subtype or diabetic status. Therefore, we conducted a large nationwide study to assess this in women with surgically resected invasive breast cancer. METHODS: Patients with newly diagnosed breast cancer between 2007 and 2016 were identified using the national health insurance claims database of South Korea. Metformin or other drug exposures was defined as medication for ≥ 90 days. Breast cancer subtypes were classified into four groups based on hormonal therapy and anti-HER2 treatments. RESULTS: A total of 117,333 patients were included (median follow-up duration, 90 months). Type 2 diabetes mellitus (T2DM) affected significantly overall survival (OS, 7 years, 89.7% vs. 92.4%, p < 0.001). A significant interaction was found between the use of metformin and insulin in patients with T2DM (p = 0.018). Thus, the subsequent analysis was limited to these patients and propensity score matching was performed. We found significantly increased OS in patients treated with metformin (7-year OS, 88.3% vs. 85.6%, p < 0.001). Interestingly, a significant effect was observed in the hormonal therapy (HT)+/HER2-targeted therapy (Tx)- group (p < 0.001), whereas no specific association was observed in the HT-/HER2 Tx- group (p = 0.220). CONCLUSIONS: Metformin administration may be associated with reduced mortality in patients with surgically resected breast cancer, particularly in the HT+/HER2 Tx- group. Clinical trials investigating metformin as a combination agent in breast cancer should stratify patients by curative resection, intrinsic subtype, the presence of T2DM, and the use of insulin.
PURPOSE: Numerous studies have suggested that metformin treatment can increase breast cancer survival; however, it is unclear whether its effects interact with intrinsic subtype or diabetic status. Therefore, we conducted a large nationwide study to assess this in women with surgically resected invasive breast cancer. METHODS:Patients with newly diagnosed breast cancer between 2007 and 2016 were identified using the national health insurance claims database of South Korea. Metformin or other drug exposures was defined as medication for ≥ 90 days. Breast cancer subtypes were classified into four groups based on hormonal therapy and anti-HER2 treatments. RESULTS: A total of 117,333 patients were included (median follow-up duration, 90 months). Type 2 diabetes mellitus (T2DM) affected significantly overall survival (OS, 7 years, 89.7% vs. 92.4%, p < 0.001). A significant interaction was found between the use of metformin and insulin in patients with T2DM (p = 0.018). Thus, the subsequent analysis was limited to these patients and propensity score matching was performed. We found significantly increased OS in patients treated with metformin (7-year OS, 88.3% vs. 85.6%, p < 0.001). Interestingly, a significant effect was observed in the hormonal therapy (HT)+/HER2-targeted therapy (Tx)- group (p < 0.001), whereas no specific association was observed in the HT-/HER2 Tx- group (p = 0.220). CONCLUSIONS:Metformin administration may be associated with reduced mortality in patients with surgically resected breast cancer, particularly in the HT+/HER2 Tx- group. Clinical trials investigating metformin as a combination agent in breast cancer should stratify patients by curative resection, intrinsic subtype, the presence of T2DM, and the use of insulin.
Authors: Julie O'Neal; Amy Clem; Lindsey Reynolds; Susan Dougherty; Yoannis Imbert-Fernandez; Sucheta Telang; Jason Chesney; Brian F Clem Journal: Breast Cancer Res Treat Date: 2016-09-09 Impact factor: 4.872
Authors: P Boyle; M Boniol; A Koechlin; C Robertson; F Valentini; K Coppens; L-L Fairley; M Boniol; T Zheng; Y Zhang; M Pasterk; M Smans; M P Curado; P Mullie; S Gandini; M Bota; G B Bolli; J Rosenstock; P Autier Journal: Br J Cancer Date: 2012-09-20 Impact factor: 7.640
Authors: Kyung Na Lee; Mylin A Torres; Alyssa N Troeschel; Jiabei He; Keerthi Gogineni; Lauren E McCullough Journal: PLoS One Date: 2020-05-05 Impact factor: 3.240
Authors: Giuseppe Buono; Anna Crispo; Mario Giuliano; Carmine De Angelis; Francesco Schettini; Valeria Forestieri; Rossella Lauria; Michelino De Laurentiis; Pietro De Placido; Carmen Giusy Rea; Carmen Pacilio; Emanuela Esposito; Maria Grimaldi; Flavia Nocerino; Giuseppe Porciello; Aldo Giudice; Alfonso Amore; Anita Minopoli; Gerardo Botti; Sabino De Placido; Meghana V Trivedi; Grazia Arpino Journal: Breast Cancer Res Treat Date: 2020-06-04 Impact factor: 4.872